Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Income towards Parent Company (2022 - 2026)

Indivior Pharmaceuticals has reported Income towards Parent Company over the past 5 years, most recently at $89.0 million for Q1 2026.

  • For Q1 2026, Income towards Parent Company rose 85.42% year-over-year to $89.0 million; the TTM value through Mar 2026 reached $251.0 million, up 3685.71%, while the annual FY2025 figure was $210.0 million, 2900.0% up from the prior year.
  • Income towards Parent Company for Q1 2026 was $89.0 million at Indivior Pharmaceuticals, down from $102.0 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $102.0 million in Q4 2025 and troughed at -$329.0 million in Q4 2022.
  • A 5-year average of $6.9 million and a median of $55.0 million in 2024 define the central range for Income towards Parent Company.
  • Biggest five-year swings in Income towards Parent Company: plummeted 438.81% in 2023 and later surged 385.71% in 2025.
  • Year by year, Income towards Parent Company stood at -$329.0 million in 2022, then skyrocketed by 120.67% to $68.0 million in 2023, then tumbled by 69.12% to $21.0 million in 2024, then surged by 385.71% to $102.0 million in 2025, then decreased by 12.75% to $89.0 million in 2026.
  • Business Quant data shows Income towards Parent Company for INDV at $89.0 million in Q1 2026, $102.0 million in Q4 2025, and $42.0 million in Q3 2025.